Although in vivo studies will be required to assess the therapeutic benefits deriving from the inhibition of CXCL8 secretion in thyroid tumor microenvironment, this could represent an alternative therapeutic strategy, at least for those minority of patients who are refractory to conventional therapies. Here, CXCL8 is linked to thyroid tumor.